0001209191-23-058774.txt : 20231215 0001209191-23-058774.hdr.sgml : 20231215 20231215162326 ACCESSION NUMBER: 0001209191-23-058774 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231213 FILED AS OF DATE: 20231215 DATE AS OF CHANGE: 20231215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SIEGALL CLAY B CENTRAL INDEX KEY: 0001167496 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40384 FILM NUMBER: 231490682 MAIL ADDRESS: STREET 1: 21823 30TH DR SE CITY: BOTHELL STATE: WA ZIP: 98021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tourmaline Bio, Inc. CENTRAL INDEX KEY: 0001827506 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 27 WEST 24TH STREET STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 646-481-9832 MAIL ADDRESS: STREET 1: 27 WEST 24TH STREET STREET 2: SUITE 702 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Talaris Therapeutics, Inc. DATE OF NAME CHANGE: 20201007 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-13 0 0001827506 Tourmaline Bio, Inc. TRML 0001167496 SIEGALL CLAY B C/O TOURMALINE BIO, INC. 27 WEST 24TH STREET, SUITE 702 NEW YORK NY 10010 1 0 0 0 0 Stock Option (Right to Buy) 18.55 2023-12-13 4 A 0 20000 0.00 A 2033-12-12 Common Stock 20000 20000 D The shares subject to the option shall vest and become exercisable in thirty-six (36) equal monthly installments beginning on January 13, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. /s/ Brad Middlekauff, Attorney-in-Fact 2023-12-15